Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

SL-172154

Fusion protein · Immune activation, directed at CD47 and CD40 · developed by Shattuck Labs

Phase 1 Most advanced trial (none active)
STTK Developer
2 Registered trials

What is SL-172154?

SL-172154 is a fusion protein made of the extracellular domains of human SIRPα and CD40 ligand linked through a human Fc domain. It binds CD47 on tumor cells, blocking the CD47/SIRPα interaction that inhibits macrophage phagocytosis, and binds CD40 on antigen-presenting cells to activate them. It is studied in squamous cell carcinomas of the head and neck and skin, acute myeloid leukemia, and myelodysplastic syndromes.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Fusion protein
Targets
CD47, CD40
Mechanism
Immune activation, directed at CD47 and CD40
Pathways
CD47/SIRPα signaling blockade and macrophage phagocytosis, calreticulin/LRP-1 pro-phagocytic signaling, CD40-mediated B-lymphocyte activation and dendritic cell activation
Therapy area
Oncology
Developer
Shattuck Labs, Inc. (STTK)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05275439 Phase 1 Acute Myeloid Leukemia Terminated STTK
NCT04502888 Phase 1 Cutaneous Squamous Cell Carcinoma Terminated STTK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Myeloid LeukemiaCutaneous Squamous Cell CarcinomaMyelodysplastic SyndromesSquamous Cell Carcinoma of Head and Neck

Other drugs acting on CD47 / CD40

More from Shattuck Labs

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the STTK page.

Follow STTK, the company behind SL-172154

See STTK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

STTK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.